tbuckley/cabot-search huggingface dataset:
Colorectal Cancer Screening Comparative Effectiveness—Clinical Trials Are Not Always The Answer—Reply
Authors: Rita F. Redberg
Journal: JAMA Internal Medicine (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
P2.06-042 Evaluate the Utility of the Computed Bioconductance Measurement in the Diagnosis of Lung Cancer
Authors: Dawei Yang, Rex Yung, Jing Li, Ningfang Wang, Xing Gong, Jingjing Lu, Ye Gu, Xiaodong Zhang, Tao Ren, Hao Wang, Wenjie Zhang, Jian Zhou, Chunxue Bai
Journal: Journal of Thoracic Oncology (2017)
Dynamics of QT Interval in a Patient With Long QT Syndrome and a Normal QT Interval
Authors: Mikiko Nakagawa, Tetsu Iwao, Shuji Ishida, Naohiko Takahashi, Hidetoshi Yonemochi, Midori Asada, Susumu Shimada, Tetsunori Saikawa, Morio Ito
Journal: Circulation (1998)

A case report of a 15-year-old girl who experienced syncope and torsades de pointes is presented. The girl had a normal QT interval (QTc=0.37 sec) on the resting electrocardiogram (ECG). Infusion of isoproterenol induced QT prolongation (QTc=0.62 sec) and frequent occurrence of multiform ventricular premature beats. Her Holter ECG showed a prolongation of the QTc interval with a shortening of the RR interval. Low-frequency power (LF) and high-frequency power (HF) of heart rate variability were evaluated from the Holter ECG. The patient showed a statistically significant negative QTc/HF and a significant positive QTc/(LF/HF) relationship, whereas none of the age- and sex-matched healthy subjects showed these relationships. The slope of the QT/RR relationship for the patient was below the lower limit of the normal range. This report describes the unusual relationship of QT interval to RR interval and heart rate variability in a long QT syndrome patient with a normal QT interval on resting ECG.
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator–controlled VOYAGE 2 trial
Authors: Kristian Reich, April W. Armstrong, Peter Foley, Michael Song, Yasmine Wasfi, Bruce Randazzo, Shu Li, Y.-K. Shen, Kenneth B. Gordon
Journal: Journal of the American Academy of Dermatology (2017)

Phase II data suggested that guselkumab, an anti-interleukin-23 monoclonal antibody, was efficacious in psoriasis.We sought to assess efficacy and safety of guselkumab in moderate to severe psoriasis versus placebo and adalimumab, including interrupted treatment and switching adalimumab nonresponders to guselkumab.Patients were randomized to guselkumab 100 mg (weeks 0 and 4, then every 8 weeks; n = 496); placebo→guselkumab (weeks 0, 4, and 12 then guselkumab at weeks 16 and 20; n = 248); or adalimumab (80 mg week 0, then 40 mg week 1, and every 2 weeks through week 23; n = 248). At week 28, guselkumab 90% or greater improvement in Psoriasis Area and Severity Index (PASI) score from baseline (PASI 90) responders were rerandomized to guselkumab or placebo with guselkumab after loss of response. Placebo→guselkumab responders and adalimumab responders received placebo, then guselkumab after loss of response. Nonresponders received guselkumab.At week 16, more patients receiving guselkumab achieved an Investigator Global Assessment (IGA) score 0/1 (cleared/minimal) (84.1% vs 8.5%) and PASI 90 (70.0% vs 2.4%) versus placebo (coprimary end points). Guselkumab was superior to adalimumab at week 16 (IGA score 0/1, 75% or greater improvement in PASI score from baseline, and PASI 90) and week 24 (IGA score 0/1 and 0, PASI 90, 100% improvement in PASI score from baseline) (P < .001). From weeks 28 to 48, better persistence of response was observed in guselkumab maintenance versus withdrawal groups (P < .001). Of adalimumab nonresponders who switched to guselkumab, 66.1% achieved PASI 90 at week 48. Guselkumab improved patient-reported outcomes. Adverse events were comparable among groups.One-year follow-up limits retreatment data.Guselkumab is a highly effective, well-tolerated, maintenance therapy, including in adalimumab nonresponders.
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial
Authors: Andrew Blauvelt, Kim A. Papp, Christopher E.M. Griffiths, Bruce Randazzo, Yasmine Wasfi, Yaung-Kaung Shen, Shu Li, Alexa B. Kimball
Journal: Journal of the American Academy of Dermatology (2017)

Guselkumab, an interleukin-23 blocker, was superior to adalimumab in treating moderate to severe psoriasis in a phase II trial.We sought to compare efficacy and safety of guselkumab with adalimumab and placebo in patients with psoriasis treated for 1 year.Patients were randomized to guselkumab 100 mg (weeks 0 and 4, then every 8 weeks; n = 329); placebo→guselkumab (weeks 0, 4, and 12 then guselkumab at weeks 16 and 20, then every 8 weeks; n = 174); or adalimumab (80 mg week 0, 40 mg week 1, then 40 mg every 2 weeks through week 47; n = 334). Physician-reported outcomes (Investigator Global Assessment, Psoriasis Area and Severity Index [PASI]), patient-reported outcomes (Dermatology Life Quality Index, Psoriasis Symptoms and Signs Diary), and safety were evaluated through week 48.Guselkumab was superior (P < .001) to placebo at week 16 (85.1% vs 6.9% [Investigator Global Assessment score of 0/1 (cleared/minimal)] and 73.3% vs 2.9% [90% or greater improvement in PASI score from baseline (PASI 90)]). Guselkumab was also superior (P < .001) to adalimumab for Investigator Global Assessment 0/1 and PASI 90 at week 16 (85.1% vs 65.9% and 73.3% vs 49.7%), week 24 (84.2% vs 61.7% and 80.2% vs 53.0%), and week 48 (80.5% vs 55.4% and 76.3% vs 47.9%). Furthermore, guselkumab significantly improved patient-reported outcomes through week 48. Adverse event rates were comparable between treatments.Analyses were limited to 48 weeks.Guselkumab demonstrated superior efficacy compared with adalimumab and was well tolerated in patients with psoriasis through 1 year.
Significance of Copy Number Alterations for Molecular Treatment Response in Childhood Acute Lymphoblastic Leukemia.
Authors: Doris Steinemann, Gunnar Cario, Martin Stanulla, Leonid Karawajew, Marcel Tauscher, Anja Weigmann, Gudrun Göhring, Wolf-Dieter Ludwig, Jochen Harbott, Bernhard Radlwimmer, Claus-Rainer Bartram, Peter Lichter, Martin Schrappe, Brigitte Schlegelberger
Journal: Blood (2007)
The effect of high dose intracoronary ADenosine Administration during Primary percutaneous coronary intervention in acute myocardial infarction - a randomized controlled Trial (ADAPT).
Authors: Marieke L. Fokkema, Pieter J. Vlaar, Mathijs Vogelzang, Youlan L. Gu, Marthe A. Kampinga, Bart J. de Smet, Rutger L. Anthonio, Gillian A. Jessurun, Ad F. van den Heuvel, Eng-Shiong Tan, Felix Zijlstra
Journal: Journal of the American College of Cardiology (2009)
Dynamics of Telomere Length and Telomerase Activity in Ph1-Negative Chronic Myeloproliferative Disorders
Authors: Ioanna Bazdiara, Despina Pantelidou, Athanasios Anastasiadis, Vassilios Papadopoulos, Dimitrios Margaritis, Emmanouil Spanoudakis, Georgios Xanthopoulidis, Ioannis Kotsianidis, Anna Christoforidou, Aggelos Goutzouvelidis, Georgios Bourikas, Konstantinos Tsatalas
Journal: Blood (2008)
Characterization and Prognostic Impact of Oligoclonal Humoral Response in Patients with Multiple Myeloma After Autologous Stem-Cell Transplantation: Long-Term Results From a Single Institution
Authors: Natalia Tovar, Carlos Fernández de Larrea, Juan I. Aróstegui, María Teresa Cibeira, Laura Rosiñol, Montserrat Rovira, Montserrat Elena, Xavier Filella, Jordi Yagüe, Joan Blade
Journal: Blood (2012)
P238 Investigating genome wide dna methylation in airway smooth muscle cells from asthmatic and non-asthmatic donors
Authors: RL Clifford, JK Patel, DE Shaw, AJ Knox, MS Kobor
Journal: Thorax (2016)

<h3>Rationale</h3> Genetic mechanisms fail to fully explain asthma pathogenesis and environmental factors are considered to play an important role. Environmental factors may lead to permanent changes in epigenetic patterns and contribute to asthma. Epigenetics is the study of heritable changes in gene expression that are not due to changes in DNA sequence. DNA methylation is a reversible modification of DNA structure in which a methyl group is added to cytosine residues. Parental smoking affects the methylation of buccal cell DNA from children and children with early onset wheeze have an altered blood DNA methylation profile to healthy individuals. No studies have compared DNA methylation profiles in the disease relevant cell type of airway smooth muscle (ASM) cells. <h3>Methods</h3> DNA was isolated from ASM cells at passage 5 and bisulphite treated to convert epigenetic information into sequence-based information. Site specific, quantitative genome wide methylation was determined using the Illumina 450K Infinium Methylation BeadChip array. Hits were validated by Pyrosequencing. RNA was extracted simultaneously for mRNA expression analysis by real time PCR. <h3>Results</h3> There were no independent CpG sites associated with asthmatic status of ASM cells following multiple test correction. Without correction over 13000 CpG sites showed a significant difference in methylation (linear modelling, p value &gt;0.05) between asthmatic and non-asthmatic cells, and a biologically relevant difference in methylation of greater that 10% (β value &gt;0.1 ). 10 of these sites were selected as top hits. 7 sites positively validated by pyrosequencing. They were associated with 7 different genes; LGALS3BP, ATP11A, ZNF696, KLF6, TBX1, RUNX3, and SPINT2. Expression of these genes was measured in ASM cells isolated from asthmatic and non-asthmatic donors. LGALS3BP expression was undetectable while ATP11A and ZNF696 displayed no difference in expression between cells from asthmatic and non-asthmatic donors. KLF6 and SPINT2 showed a trend towards increased expression in cells from asthmatic donors while RUNX3 and TBX1 showed a trend towards decreased expression. <h3>Conclusions</h3> Differences in CpG methylation exist between ASM isolated from asthmatic and non-asthmatic donors. Future work will focus on identifying differentially methylated regions of DNA and further defining the association to gene and protein expression.
An angiotensin II type 1 receptor binding molecule has a critical role in hypertension in a chronic kidney disease model
Authors: Ryu Kobayashi, Hiromichi Wakui, Kengo Azushima, Kazushi Uneda, Sona Haku, Kohji Ohki, Kotaro Haruhara, Sho Kinguchi, Miyuki Matsuda, Masato Ohsawa, Yoshiyuki Toya, Akira Nishiyama, Akio Yamashita, Katsuyuki Tanabe, Yohei Maeshima, Satoshi Umemura, Kouichi Tamura
Journal: Kidney International (2017)
Significant Improvement of Survival By T2* Cardiovascular Magnetic Resonance in Thalassemia Major
Authors: Alessia Pepe, Antonella Meloni, Giovanni Carlo Del Vecchio, Maria Antonietta Romeo, Maria Rita Gamberini, Federico Bonetti, Maria Giovanna Neri, Elisabetta Chiodi, Vincenzo Positano, Aurelio Maggio, Caterina Borgna-Pignatti
Journal: Blood (2015)
P12 Exploring the characteristics of patients with mesothelioma who decline chemotherapy: a prospective cohort of 200 patients
Authors: AC Bibby, D De Fonseka, AJ Morley, E Keenan, A Addeo, S Smith, AJ Edey, NA Maskell
Journal: Thorax (2016)

<h3>Introduction</h3> Malignant pleural mesothelioma (MPM) is an aggressive cancer with a poor prognosis. Treatment options are limited, and pemetrexed and cisplatin chemotherapy is the only intervention shown to extend life. Promising new therapies may provide alternate treatment options in the future. Chemotherapy uptake varies in MPM. Some centres report rates as low as 46% in eligible patients. The aim of this study was to explore the characteristics of patients who declined chemotherapy, and to determine which factors were associated with chemotherapy refusal. <h3>Methods</h3> Prospective data were collected on all patients diagnosed with MPM in one UK tertiary referral centre. Diagnosis of MPM and eligibility for chemotherapy were determined at the regional MPM multidisciplinary meeting. Patients were followed up until death or censored on 13/7/16. Patient characteristics were compared using chi-squared, Fishers Exact and unpaired T-tests. Kaplan Meier curves were drawn to compare survival between patients who accepted and declined chemotherapy. Logistic regression was used to assess associations between patient characteristics and chemotherapy uptake. <h3>Results</h3> 200 patients were diagnosed with MPM between 1/3/08 and 8/6/16. 150 (75%) were eligible for chemotherapy. 93/150 (62%) patients received chemotherapy, 46/150 (31%) declined and 11/150 (7.3%) patients did not receive it for other reasons. Patient characteristics are shown in Table 1. The group who declined chemotherapy were older (mean age 74.4 vs 68.4, p &lt; 0.001), with a higher proportion of females (23.9% vs 10.8%, p = 0.041) and fewer patients with performance status (PS) 0 (17.4% vs 43%, p = 0.005). Patients who received chemotherapy had longer median survival (426 days vs 203 days, p = 0.001, HR 0.519, p = 0.015). The factors associated with chemotherapy refusal were age (regression coefficient 0.144, p &lt; 0.001) and PS ≥ 1 (coefficient 1.052, p = 0.027). <h3>Conclusion</h3> This is the first study to report the characteristics of MPM patients who declined chemotherapy. Significant differences were seen compared with patients who received chemotherapy. Further research is needed to determine whether similar patterns are seen in other centres. Reasons for refusal were not collected, but the association with age and worse performance status may reflect concerns about chemotherapy toxicity. Qualitative research could explore patients’ reasons for refusing chemotherapy.
P229 Breath-taking outcomes: evaluation of a specialist breathlessness clinic
Authors: L Douglas, A English, GP Obita, SP Hart, MG Crooks
Journal: Thorax (2016)

<h3>Background</h3> Breathlessness is distressing for patients and is a common reason for emergency department attendance. Chronic refractory breathlessness is associated with anxiety, embarrassment and fear, and effective management is essential to improve quality of life and reduce hospital admissions.<sup>1</sup> Interventions such as breathing control, activity pacing and anxiety management are beneficial.<sup>2</sup> This study examined the effect of attending a dedicated respiratory physiotherapist led breathlessness service on patient reported outcomes. <h3>Method</h3> Patients attending the breathlessness clinic between April 2015 and April 2016 completed Numerical Rating Scales (NRS) out of 10 to grade their breathlessness. Data were collected before and 1–2 weeks after clinic attendance. Lower NRS scores represented a lower symptom burden. A change of 1 or more on the NRS was considered clinically significant. Responses were compared using t-tests and Wilcoxon signed-rank tests. Data are presented as mean ± SD. <h3>Results</h3> Fifty-two patients attended the breathless clinic during the study period (mean age 73, range 49–92 years). Patients had a range of diagnoses causing their breathlessness with idiopathic pulmonary fibrosis (44.2%), lung cancer (19.2%), and non-specified interstitial lung disease (11.5%) being most common. Significant improvements were observed across all domains. Average breathlessness experienced in the past 24 hours reduced from 3.9 ± 1.7 to 3.6 ± 1.6 (p = 0.001). The worst breathlessness experienced in the past 24 hours reduced by 1 point to 6.3 ± 1.9 (p &lt; 0.001). The distress experienced from breathlessness reduced from 5.8 ± 6.4 to 4.8 ± 4.8 (p &lt; 0.001). Patients’ perceived ability to cope with their breathlessness improved by 1 point (p &lt; 0.001). <h3>Conclusions</h3> A specialist breathlessness clinic provided a valuable service for patients with chronic refractory breathlessness. Significant, clinically meaningful benefits were observed in terms of the severity of breathlessness that patients experienced. Furthermore, patients perceived a reduction in distress and increased ability to cope. <h3>References</h3> Ekström M, Abernethy A, Currow D. The management of chronic breathlessness in patients with advanced and terminal illness. <i>BMJ</i> 2015;<b>349</b>:g7617. Higginson IJ, Bausewein C, Reilly C, <i>et al</i>. An integrated palliative and respiratory care service for patients with advanced disease and refractory breathlessness: a randomised controlled trial. Lancet Respiratory Medicine2014;2:979–87.
P3.02b-090 Pemetrexed versus Gefitinib in EGFR Mutation Positive Lung Cancer: Results of a Phase 3 Study from India
Authors: Kumar Prabhash, Vijay Patil, Amit Joshi, Vanita Noronha, Anuradha Chougule, Abhishek Mahajan, Amit Janu, Supriya Goud, Sucheta More, Rajiv Kaushal, Ashay Karpe, Anant Ramaswamy, Nikhil Pande, Vikas Talreja, Alok Goel
Journal: Journal of Thoracic Oncology (2017)
Low Dose Synthetic Human Atrial Natriuretic Peptide Infusion in a Patient With Mitral Stenosis and Severe Pulmonary Hypertension
Authors: Keiko Maeda, Takayoshi Tsutamoto, Atsuyuki Wada, Tomoko Hisanaga, Tamaki Nishimura, Hisao Yamada, Yasushi Sasaki, Masahiko Kinoshita
Journal: Circulation (1999)

The present report concerns a case of very low plasma levels of atrial natriuretic peptide (ANP) accompanying severe pulmonary hypertension due to mitral stenosis. There was remarkable fibrosis in the atrium and ANP secretion may have been insufficient. Low-dose infusion (0.025 microg kg(-1) min(-1)) of synthetic human alpha-ANP infusion was very effective in improving the pulmonary hypertension.
DNA Hypomethylation Leads to Aberrant Expression of PD-1 in Chronic Lymphocytic Leukemia
Authors: Eun Joon Lee, Jimei Liu, Ethan Speir, James Wilson, Hena Joshi, Lirong Pei, Junfeng Luo, Farrukh Awan, David Munn, Xiao-Jie Yan, Nicholas Chiorazzi, Huidong Shi
Journal: Blood (2012)
OA19.06 Adjuvant Chemotherapy Decisions Based on Molecular Risk Status Improves Outcomes in Early Stage, Non-Small Cell Lung Cancer
Authors: Gavitt Woodard, Jane Crockard, Clara Zoon-Besselink, Johannes Kratz, Matthew Gubens, Thierry Jahan, Collin Blakely, Kirk Jones, Michael Mann, David Jablons
Journal: Journal of Thoracic Oncology (2017)
Impact of Early Factor VIII Exposure, Prophylaxis and Prenatal/Perinatal Events on Inhibitor Risk in Children with Hemophilia A: A Case-Control Study.
Authors: Elena Santagostino, Angiola Rocino, Maria E. Mancuso, Maria G. Mazzucconi, Giacomo Mancuso, Maria Messina, Annarita Tagliaferri, Matteo Luciani, Elio Boeri, Pier M. Mannucci
Journal: Blood (2004)
Treatment with Bortezomib Overcomes Resistance to Imatinib in Ph-Leukemia Quiescent Cells.
Authors: Yachiyo Kuwatsuka, Yosuke Minami, Ryohei Tanizaki, Miho Minami, Akihiro Abe, Yuka Nomura, Hitoshi Kiyoi, Tomoki Naoe
Journal: Blood (2009)
MA09.02 Pembrolizumab + Carboplatin and Pemetrexed as 1st-Line Therapy for Advanced Non–Small Cell Lung Cancer: KEYNOTE-021 Cohort G
Authors: Corey Langer, Shirish Gadgeel, Hossein Borghaei, Vassiliki Papadimitrakopoulou, Amita Patnaik, Steve Powell, Ryan Gentzler, Renato Martins, James Stevenson, Shadia Jalal, Amit Panwalkar, James Chih-Hsin Yang, Matthew Gubens, Lecia Sequist, Joseph Fiore, Joy Ge, Harry Raftopoulos, Leena Gandhi
Journal: Journal of Thoracic Oncology (2017)
Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study
Authors: Elizabeth R Plimack, Joaquim Bellmunt, Shilpa Gupta, Raanan Berger, Laura Q M Chow, Jonathan Juco, Jared Lunceford, Sanatan Saraf, Rodolfo F Perini, Peter H O'Donnell
Journal: The Lancet Oncology (2017)
P3.03-039 Prognostic Biomarkers for Malignant Pleural Mesothelioma Treated with Chemotherapy
Authors: Hakan Akgun, Selma Metintas, Guntulu Ak, Secil Demirkol, Resat Aydın, Murat Isbilen, Ali Gure, Muzaffer Metintas
Journal: Journal of Thoracic Oncology (2017)
Cytotoxicity Is Not Required for the Anti-Leukemia Efficacy of Human H-Y-Specific CD4+ T Lymphocytes In Vivo.
Authors: Attilio Bondanza, Lothar Hambach, Zohara Aghai, Monica Casucci, Bart Nijmeijer, Fabio Ciceri, Chiara Bonini, Els Goulmy
Journal: Blood (2009)
Possible Reduced Immunogenicity of Chromatin Modifying Agents Expanded Cord Blood Grafts Is Likely Due to STAT3 Inhibition,
Authors: Benjamin Petro, Kazumi G Yoshinaga, Dolores Mahmud, Simona Taioli, Santosh Saraf, Amer Sidani, John G. Quigley, Damiano Rondelli, Nadim Mahmud
Journal: Blood (2011)
P3.02c-097 Nivolumab in Elderly or Poor Performance Status Patients with Advanced Non-Small Cell Lung Cancer
Authors: Sho Watanabe, Yasushi Goto, Noriko Motoi, Keiko Goto, Hideaki Shiraishi, Kota Itahashi, Hidehito Horinouchi, Shintaro Kanda, Yutaka Fujiwara, Hiroshi Nokihara, Noboru Yamamoto, Yuichiro Ohe
Journal: Journal of Thoracic Oncology (2017)
Valproic Acid Accelerates Cell Cycle Progression of Hematopoietic Stem Cells Via the Activation of GSK3beta-Dependent Signaling Pathways.
Authors: Gesine Bug, Hilal Gul, Kerstin Schwarz, Manuela Kampfmann, Xiaomin Zheng, Tim Beissert, Dieter Hoelzer, Oliver G. Ottmann, Martin Ruthardt
Journal: Blood (2004)
P2.04-045 Management of Malignant Pleural Effusions: Ten Years’ Experience of a Single Center
Authors: Fatmir Caushi, Danjela Xhemalaj, Ilir Skenduli, Arjan Mezini, Hasan Hafizi, Zyber Pupla, Alban Hatibi, Irma Bani
Journal: Journal of Thoracic Oncology (2017)
Immunogenecity of CML-DC Is Maintained upon Imatinib Mesylate: Implication for Vaccination Regimens.
Authors: Theresia M. Westers, Jeroen J.W.M. Janssen, Niels C.L. Snoijs, Arjan A. van de Loosdrecht, Gert J. Ossenkoppele
Journal: Blood (2004)